<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: To report a patient with <z:e sem="disease" ids="C0406686" disease_type="Disease or Syndrome" abbrv="">diabetic rubeosis</z:e> who suffered from <z:hpo ids='HP_0011009'>acute</z:hpo> <z:chebi fb="46" ids="15035">retinal</z:chebi> ischemic change and <z:hpo ids='HP_0001297'>stroke</z:hpo> after intravitreal injection of bevacizumab </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: A 55-year-old man had <z:mp ids='MP_0002055'>diabetes</z:mp> with unilateral rubeosis and macular <z:hpo ids='HP_0000969'>edema</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Three days after receiving intravitreal injection of bevacizumab (1.25 mg in 0.1 ml), he developed <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0456909" disease_type="Disease or Syndrome" abbrv="">vision loss</z:e> and change of consciousness </plain></SENT>
<SENT sid="3" pm="."><plain>A complete ocular examination, <z:chebi fb="0" ids="31624">fluorescein</z:chebi> angiography, carotid artery Doppler sonography and brain magnetic resonance imaging were performed </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Best corrected visual acuity before injection was 6/60 in the left eye </plain></SENT>
<SENT sid="5" pm="."><plain>He had underlying left carotid <z:mp ids='MP_0006135'>artery stenosis</z:mp> combined with bilateral preproliferative diabetic <z:hpo ids='HP_0000488'>retinopathy</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Three days after intravitreal injection of bevacizumab, <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C1321558" disease_type="Disease or Syndrome" abbrv="">ocular ischemic syndrome</z:e> occurred </plain></SENT>
<SENT sid="7" pm="."><plain>He also suffered from <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001297'>stroke</z:hpo>, and brain magnetic resonance angiography showed total left internal carotid <z:mp ids='MP_0006134'>artery occlusion</z:mp> </plain></SENT>
<SENT sid="8" pm="."><plain>The final visual acuity was no light perception in the left eye and 3/6 in the right eye </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: Patients receiving intravitreal injections of bevacizumab should be evaluated for potential systemic risk factors such as carotid insufficiency, <z:hpo ids='HP_0003256'>coagulopathy</z:hpo> and poorly controlled <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain><z:hpo ids='HP_0011009'>Acute</z:hpo> ocular ischemic change may be associated with intravitreal injection of bevacizumab in patients with vascular compromised diabetic <z:hpo ids='HP_0000488'>retinopathy</z:hpo> and/or underlying stenosis of the carotid artery </plain></SENT>
</text></document>